Live Updates: COVID-19 Cases
  • World 21,100,473
    World
    Confirmed: 21,100,473
    Active: 6,393,543
    Recovered: 13,948,929
    Death: 758,001
  • USA 5,416,014
    USA
    Confirmed: 5,416,014
    Active: 2,401,950
    Recovered: 2,843,642
    Death: 170,422
  • Brazil 3,229,621
    Brazil
    Confirmed: 3,229,621
    Active: 767,417
    Recovered: 2,356,640
    Death: 105,564
  • India 2,464,316
    India
    Confirmed: 2,464,316
    Active: 663,310
    Recovered: 1,752,829
    Death: 48,177
  • Russia 912,823
    Russia
    Confirmed: 912,823
    Active: 174,361
    Recovered: 722,964
    Death: 15,498
  • South Africa 572,865
    South Africa
    Confirmed: 572,865
    Active: 123,978
    Recovered: 437,617
    Death: 11,270
  • Peru 507,996
    Peru
    Confirmed: 507,996
    Active: 134,342
    Recovered: 348,006
    Death: 25,648
  • Mexico 505,751
    Mexico
    Confirmed: 505,751
    Active: 108,951
    Recovered: 341,507
    Death: 55,293
  • Chile 380,034
    Chile
    Confirmed: 380,034
    Active: 16,604
    Recovered: 353,131
    Death: 10,299
  • Spain 355,856
    Spain
    Confirmed: 355,856
    Active: 327,251
    Recovered: ?
    Death: 28,605
  • Iran 338,825
    Iran
    Confirmed: 338,825
    Active: 25,683
    Recovered: 293,811
    Death: 19,331
  • UK 313,798
    UK
    Confirmed: 313,798
    Active: 272,451
    Recovered: ?
    Death: 41,347
  • Saudi Arabia 294,519
    Saudi Arabia
    Confirmed: 294,519
    Active: 30,823
    Recovered: 260,393
    Death: 3,303
  • Pakistan 287,300
    Pakistan
    Confirmed: 287,300
    Active: 15,932
    Recovered: 265,215
    Death: 6,153
  • Bangladesh 271,881
    Bangladesh
    Confirmed: 271,881
    Active: 111,667
    Recovered: 156,623
    Death: 3,591
  • Italy 252,235
    Italy
    Confirmed: 252,235
    Active: 14,081
    Recovered: 202,923
    Death: 35,231
  • Turkey 245,635
    Turkey
    Confirmed: 245,635
    Active: 11,666
    Recovered: 228,057
    Death: 5,912
  • Germany 222,269
    Germany
    Confirmed: 222,269
    Active: 12,188
    Recovered: 200,800
    Death: 9,281
  • France 209,365
    France
    Confirmed: 209,365
    Active: 95,505
    Recovered: 83,472
    Death: 30,388
  • Canada 121,234
    Canada
    Confirmed: 121,234
    Active: 4,666
    Recovered: 107,553
    Death: 9,015
  • China 84,786
    China
    Confirmed: 84,786
    Active: 690
    Recovered: 79,462
    Death: 4,634
  • Netherlands 61,204
    Netherlands
    Confirmed: 61,204
    Active: 55,039
    Recovered: ?
    Death: 6,165
  • Australia 22,743
    Australia
    Confirmed: 22,743
    Active: 9,018
    Recovered: 13,350
    Death: 375
  • S. Korea 14,873
    S. Korea
    Confirmed: 14,873
    Active: 705
    Recovered: 13,863
    Death: 305
  • New Zealand 1,602
    New Zealand
    Confirmed: 1,602
    Active: 49
    Recovered: 1,531
    Death: 22

WHO endorses Truenat tests by ICMR, 2 others for TB diagnosis, rifampicin resistance detection

Author at TechGenyz Insights
Microscope Tests
Man Seeing Through Microscope Foe Testing. Credit: @luvqs/Unsplash

The World Health Organization (WHO) has endorsed rapid molecular Truenat assays by three research bodies, including ICMR, for initial diagnosis of tuberculosis (TB) and subsequent detection of rifampicin resistance in adults and children.

Rifampicin is a standardized drug that is used to treat Tuberculosis.

In a joint statement, the Foundation for Innovative New Diagnostics (FIND), Molbio Diagnostics and the Indian Council of Medical Research (ICMR) said the WHO has now endorsed three of their rapid molecular Truenat TM assays for initial diagnosis of TB and subsequent detection of rifampicin resistance in adults and children.

“Both Truenat MTB and Truenat MTB Plus detect Mycobacterium tuberculosis bacteria for TB diagnosis, while Truenat MTB-RIF Dx identifies resistance to rifampicin, the most commonly used first-line treatment.

“All three tests are run on the portable, battery-operated Truenat device and provide results in less than an hour,” they said in a statement.

Noting that TB remains the leading cause of death from an infectious disease worldwide, with around 10 million cases and 1.5 million deaths in 2018, they said drug-resistant TB poses a particular challenge, with growing resistance to rifampicin and other drugs that treat the disease.

“In 2018, around half-a-million new cases of rifampicin resistant TB were diagnosed. Urgent action is needed to close the gap in TB diagnosis and treatment, particularly in low-resource settings, to reach the WHO target of ending TB by 2030,” the statement said.

To that end, bringing sensitive TB diagnosis and drug susceptibility testing closer to patients is a key priority for global TB control, but requires robust point-of-care diagnostic tests that are easily implementable at lower levels of the healthcare system, it said.

“This is a matter of pride for ICMR, Department of Health Research (DHR), New Delhi. It was a long journey to advance indigenous diagnostic technologies for the diagnosis of TB and MDR/XDR-TB. Truenatis already accepted for use under the NTEP in India.

“Endorsement of Truenat by WHO will enable other low-and middle-income countries to procure Truenat for diagnosis of TB and rifampicin resistance, thus supporting TB elimination in developing countries,” the statement quoting Balram Bhargava, Secretary DHR and Director General – ICMR said.

Career

Subscribe